Crossmark Global Holdings Inc. Acquires 9,781 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Crossmark Global Holdings Inc. grew its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDYFree Report) by 328.3% in the fourth quarter, Holdings Channel reports. The firm owned 12,760 shares of the company’s stock after acquiring an additional 9,781 shares during the period. Crossmark Global Holdings Inc.’s holdings in Dr. Reddy’s Laboratories were worth $201,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Farther Finance Advisors LLC raised its position in Dr. Reddy’s Laboratories by 43.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock valued at $36,000 after purchasing an additional 137 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Dr. Reddy’s Laboratories during the third quarter valued at $60,000. Van ECK Associates Corp raised its holdings in shares of Dr. Reddy’s Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock valued at $64,000 after acquiring an additional 322 shares in the last quarter. GAMMA Investing LLC grew its holdings in Dr. Reddy’s Laboratories by 369.9% during the 4th quarter. GAMMA Investing LLC now owns 6,799 shares of the company’s stock worth $107,000 after acquiring an additional 5,352 shares in the last quarter. Finally, Abacus Wealth Partners LLC purchased a new position in Dr. Reddy’s Laboratories during the 4th quarter valued at about $160,000. 3.85% of the stock is currently owned by institutional investors.

Dr. Reddy’s Laboratories Stock Down 2.5 %

Dr. Reddy’s Laboratories stock opened at $13.66 on Tuesday. The business’s 50-day moving average price is $14.86 and its 200 day moving average price is $15.50. The company has a quick ratio of 1.36, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The firm has a market cap of $11.40 billion, a price-to-earnings ratio of 21.81 and a beta of 0.51. Dr. Reddy’s Laboratories Limited has a 52 week low of $13.59 and a 52 week high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDYGet Free Report) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 18.53% and a net margin of 17.81%. As a group, sell-side analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.81 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on RDY. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Finally, Barclays cut their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th.

Read Our Latest Research Report on Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Profile

(Free Report)

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

Further Reading

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr. Reddy’s Laboratories Limited (NYSE:RDYFree Report).

Institutional Ownership by Quarter for Dr. Reddy's Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.